Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options

Journal of Viral Hepatitis
G V Papatheodoridis, E Cholongitas

Abstract

A significant proportion of chronic hepatitis C patients fails to achieve sustained virologic response even after treatment with the current, more potent, combination of pegylated interferon-alpha (IFNa) plus ribavirin. Such patients represent a rather heterogeneous group and may be divided initially into relapsers and nonresponders. Both the type of previous therapy and of previous response are very important factors for the indication and the type of re-treatment. The combination of pegylated IFNa and ribavirin seems to be a rational approach for patients who failed to respond to IFNa monotherapy. Pegylated IFNa-based regimens appear to induce sustained responses in 40-68% of relapsers but in only 11% of nonresponders to previous therapy with standard IFNa plus ribavirin. Thus, new therapeutic approaches are needed for the latter subgroup of patients as well as those who fail to respond to pegylated IFNa-based regimens. Such new approaches currently under evaluation include the triple combination of pegylated IFNa, ribavirin, and amantadine, alternative types of IFN, use of agents with ribavirin like activity but lesser degrees of side-effects, inhibitors of hepatitis C virus (HCV) replication, mainly inhibitors of NS3 protea...Continue Reading

References

Sep 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D C RockeyS L Friedman
Dec 15, 1995·Annals of Internal Medicine·A M Di BisceglieJ H Hoofnagle
Sep 26, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K L Lindsay
Mar 21, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P MathurinT Poynard
Apr 16, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K E ShermanZ D Goodman
Apr 16, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E J HeathcoteL M Blatt
Apr 16, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·W C ChowP Marcellin
May 5, 1998·Journal of Hepatology·C CammàA Craxì
Aug 26, 1998·Biochemistry·F MartinM Sollazzo
Sep 19, 1998·Clinical and Diagnostic Virology·P J WelchJ R Barber
Feb 18, 1999·Journal of Medical Virology·T WakitaJ R Wands
Jan 6, 2000·Journal of Hepatology·C FerrariF Fiaccadori
Jan 6, 2000·Journal of Hepatology·A CraxïM Giunta
Jan 6, 2000·Journal of Hepatology·M Buti, R Esteban
Jan 6, 2000·Journal of Hepatology·S PolC Bréchot
Jan 6, 2000·Journal of Hepatology·B Lavezzo, M Rizzetto
Feb 5, 2000·Drugs in R&D
Mar 8, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D G MacejakL M Blatt
Jun 28, 2000·Journal of Viral Hepatitis·W G Cooksley
Aug 29, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P A LeeJ A Sandberg
Oct 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T PoynardJ Albrecht
Nov 22, 2000·The Journal of Clinical Investigation·N Usman, L M Blatt
Dec 22, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S J ChengJ B Wong
May 29, 2001·Current Medicinal Chemistry·C SteinkühlerV G Matassa
Aug 2, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H MiyakawaM E Gershwin
Aug 2, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·F A CrocenziM G Roma
Aug 2, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M G Donner, D Keppler

❮ Previous
Next ❯

Citations

Nov 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ellen M Tedaldi
Feb 7, 2007·FEBS Letters·Carylyn J MarekMatthew C Wright
Nov 3, 2006·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·M BassoA Picciotto
Feb 21, 2008·Alimentary Pharmacology & Therapeutics·E Cholongitas, G V Papatheodoridis
Dec 24, 2010·Journal of Clinical Pharmacy and Therapeutics·M Trapero-MarugánR Moreno-Otero
Jul 5, 2008·Digestive Diseases·George V Papatheodoridis
Mar 16, 2006·European Journal of Gastroenterology & Hepatology·Nikolaos V ChrysanthosAthanasios J Archimandritis
Jun 17, 2006·Pharmaceutical Research·Patrick Couvreur, Christine Vauthier
Feb 23, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Zhi-Qian WangYong-Jun Wang
Sep 4, 2015·World Journal of Gastroenterology : WJG·Evangelos CholongitasGeorge Papatheodoridis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.